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A B S T R A C T
The JAK–STAT signal transduction pathway is responsible for mediating signals of over ﬁfty cytokines, growth
factors and hormones. Signaling through the JAK–STAT pathway is regulated on multiple levels, including in-
tramolecular regulation by the JAK pseudokinase domain, and intermolecular regulation by a host of regulatory
proteins. The advent of accessible genomic tools have provided a wealth of information on disease-associated
mutations in the JAK–STAT pathway and its regulatory components. The vast number of these mutations in
diseases ranging from immunodeﬁciencies and obesity to many cancers highlight the importance of correct
regulation of JAK–STAT signaling for biological processes such as hematopoiesis, regulation of the immune
system, metabolism, and growth. Simultaneously, JAK inhibitors are gaining traction in clinical use, both for
treatment of diseases driven by JAK mutations, and for a host of inﬂammatory disorders, in which proin-
ﬂammatory cytokine signaling through the JAK–STAT pathway is an integral part of pathogenesis. The eluci-
dation of molecular mechanisms in the pathogenesis of complex diseases has also, however, brought the lim-
itations of our current understanding on the regulation of cytokine signaling to the foreground. Indeed, deeper
understanding of these regulatory mechanisms are a prerequisite for the development of the next generation of
pharmacological modulators of the JAK–STAT pathway. In this review we discuss the current state of knowledge
of the intra- and intermolecular regulation of the JAK–STAT pathway, with a focus on diseases arising from
disruptions in the regulatory apparatus.
1. Introduction
Hematopoietic cytokines play a critical role in orchestrating fun-
damental processes such as the immune response and hematopoiesis,
but also cell diﬀerentiation and growth. Thereby it is not surprising that
the central cytokine signaling pathway through Janus kinases (JAKs)
and signal transducer and activator of transcription (STAT) transcrip-
tion factors has been shown to either cause or participate in
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tumorigenesis. The ﬁrst demonstration of this were the identiﬁcation of
rare oncogenic fusions involving the JAK kinase domain, e.g., the TEL/
ETV6-JAK2 translocation resulting in leukemia driven by constitutively
dimeric and active JAK2 kinase domain [1]. Subsequently, several
other JAK2 fusions have been identiﬁed [2] as well as JAK2 gene am-
pliﬁcations in lymphomas [3] and triple-negative breast cancer [4].
Nevertheless, somatic JAK driver mutations are most commonly found
in hematological malignancies, where a single oncogenic JAK2
mutation, JAK2 V617F, underlies more than half of all classical mye-
loproliferative neoplasm (MPN) cases (reviewed in [5,6]). JAK muta-
tions are also common in leukemia, where, e.g., somatic JAK1 muta-
tions are found in 10–20% of T-cell acute lymphoblastic leukemia (T-
ALL) and JAK2 mutations in∼ 20% of down syndrome-associated B-
ALL [5].
Recently, (epi)genetic changes in JAKs, STATs, as well as regulatory
components of the pathway have also been increasingly linked to other
Table 1
Type I and II cytokines, their receptor chain conﬁgurations, as well as the corresponding JAKs and STATs are shown. JAKs and STATs critical for signaling identiﬁed
with the highest conﬁdence are shown in bold, associated JAKs and STATs for which the data is weaker are shown in parentheses. Cytokines that signal through the
same receptor-JAK–STAT conﬁguration are separated by commas. Synonyms are separated by a slash. In case of three or more often-used synonyms and for
additional explanations, see footnotes.
Cytokine Receptor chain(s) JAKs STATs References
TYPE II CYTOKINE
RECEPTORS
IFN family IFN-I (typeI)* IFNAR1 IFNAR2 JAK1, TYK2 STAT1, STAT2, STAT3,
STAT4 (STAT5, STAT6)
[154,155]
IFN-γ (typeII) IFNGR1 IFNGR2 JAK1, JAK2 STAT1 [150,154,155]
IL-28a, IL-28b, IL-
29‡
IL-28R/
IFNLR1
IL-10Rβ JAK1, TYK2 STAT1, STAT2, STAT3,
STAT5
[154,156–158]
IL-10 IL-10Rα IL-10Rβ JAK1, TYK2 STAT3, STAT1 [154–156]
IL-19 IL-20Rα IL-20Rβ JAK1, JAK2 STAT3, STAT1 [150,154,156]
IL-20, IL-24/mda7 IL-20Rα or IL-
22R
IL-20Rβ JAK1, JAK2 STAT3, STAT1 [150,151,154,156]
IL-22/IL-TIF† IL-22R IL-10Rβ JAK1, TYK2 STAT3, STAT1, (STAT5) [150,154]
IL-26/AK155 IL-20Rα IL-10Rβ JAK1, TYK2 STAT3, STAT1 [151,154,156]
TYPE I CYTOKINE
RECEPTORS
gp130
family
IL-6 IL-6Rα gp130 JAK1, JAK2,
TYK2
STAT3, STAT1 [90,154,155]
IL-11 IL-11Rα gp130 JAK1, JAK2,
TYK2
STAT3, STAT1 [90,154,155]
LIF LIFRβ gp130 JAK1, JAK2,
TYK2
STAT3, STAT1 [90,154,155,159]
CNTF CNTFRα LIFRβ gp130 JAK1, (JAK2,
TYK2)
STAT3, (STAT1) [90,154,155,160]
CLCF1§, NP CNTFRα LIFRβ gp130 JAK1, (JAK2) STAT3, STAT1 [90,154,160]
CT-1 CNTFRα LIFRβ gp130 JAK1, (JAK2,
TYK2)
STAT3 [90,154,155]
OSM OSMRβ or
LIFRβ
gp130 JAK1, (JAK2,
TYK2)
STAT3, STAT1 [90,154,155,159]
IL-31 IL-31Rα/
GLMR
OSMRβ JAK1, (JAK2) STAT3, STAT5, STAT1 [154,161]
G-CSF GCSFR/
CSF3R
JAK1, (JAK2) STAT3 [90,154,155]
Leptin LEPR/OBR JAK2 STAT3 [154]
IL-12 (p35+p40) IL-12Rβ2 IL-12Rβ1 TYK2, JAK2 STAT4 [153–155]
IL-23 (p19+p40) IL-23R IL-12Rβ1 TYK2, JAK2 STAT3, STAT4, STAT1 [153,154]
IL-27 (p28+EBI3)|| IL-27Rα¶ gp130 JAK1, JAK2,
TYK2
STAT1, STAT3, STAT4,
(STAT5)
[90,153,154]
IL-35 (p35+EBI3)# IL-12Rβ2 gp130 JAK1, JAK2 STAT1, STAT4 [153,154]
γc family IL-2 IL-2Rα IL-2Rβ γc JAK1, JAK3,
(JAK2)
STAT5, (STAT3) [90,154,155,162]
IL-4 IL-4Rα γc JAK1, JAK3 STAT6 [90,154,155,162]
IL-7 IL-7Rα γc JAK1, JAK3 STAT5, (STAT3) [90,154,155,162]
IL-9 IL-9Rα γc JAK1, JAK3 STAT5, STAT3 [90,154,155,162]
IL-15 IL-15Rα IL-2Rβ γc JAK1, JAK3 STAT5, (STAT3) [90,154,162]
IL-21 IL-21R γc JAK1, JAK3 STAT3, STAT5, (STAT1) [90,154,162]
TSLP IL-7Rα TSLPR/
CRLF2
JAK1, JAK2 STAT1, STAT3, STAT4,
STAT5, STAT6
[154,162,163]
IL-13 IL-4Rα IL-13R JAK1, JAK2,
TYK2
STAT6, (STAT3) [154,155,162]
IL-3/βc IL-3 IL-3Rα βc (gp140) JAK2, JAK1 STAT5, STAT3 [90,154,155,164]
IL-5 IL-5Rα βc (gp140) JAK2 STAT5, STAT1, STAT3 [90,154,155]
GM-CSF GM-CSF-Rα βc (gp140) JAK2 STAT5 [90,154,155]
Single
chain
EPO EPOR JAK2 STAT5
GH GHR JAK2 STAT5, (STAT3)
PRL PRLR JAK2 STAT5
TPO TPOR/MPL JAK2 STAT5
* In humans this family consists of 12 IFN-αs, IFN-ω and Limitin (a.k.a. IFN-ζ).
† IL-22 also has a soluble receptor IL-22BP, which probably works as an agonist in vivo [150,151].
‡ Interleukins 28 and 29 are also called Type III IFNs, or IFN-λs, as follows: IL-29/IFN-λ1, IL-28a/IFN-λ2, and IL-28b/IFN-λ3.
§ a.k.a. CLC, CLF, NNT-1, BSF-3; CLCF1 is secreted either with sCNTFR or CRLF1.
|| IL-27 p28 subunit is also called IL-30, which might signal through IL-6Rα [152].
¶ a.k.a. WSX-1, TCCR.
# IL-35 has also been reported to signal through IL-12Rβ2 or gp130 homodimers [153].
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cancers. Examples include hepatitis B-associated hepatocellular carci-
noma (JAK1 mutations in∼9% of patients), large granular lymphocytic
leukemia (STAT3 mutations in 40% of patients), prostate cancer (am-
pliﬁcation of STAT5A/B locus) and non-small cell lung cancer (NSCLC,
hypermethylation of suppressor of cytokine signaling (SOCS) 3 pro-
moter) (reviewed in [7]). Furthermore, several cytokines, particularly
interleukin (IL-)6 mediate critical signals for the growth of solid tumors,
and inhibition of JAK kinases by small-molecular weight inhibitors has
been shown to eﬃciently abrogate tumor formation or restore sensi-
tivity to other protein tyrosine kinase (PTK) inhibitors in xenograft
models [8,9]. Currently, clinical JAK inhibition is focused on the
treatment of MPNs [10] and rheumatoid arthritis (RA) [11], and clin-
ical trials with JAK inhibitors are ongoing also in other autoimmune
and inﬂammatory diseases [12]. Mounting evidence of the involvement
of the JAK–STAT pathway in cancer, however, has already led to
clinical trials with JAK inhibitors in, e.g., pancreatic cancer [13], ad-
vanced solid tumors (ClinicalTrials identiﬁer: NCT02646748), NSCLC
(NCT02917993), and triple-negative breast cancer (NCT02876302).
The majority of clinical JAK mutations concentrate in the pseudo-
kinase domain of the protein and highlight the importance of under-
standing the molecular mechanisms of normal and pathogenic JAK
signaling. Given the prevalence of JAK mutations as well as the broad
involvement of JAK-mediated signaling in disease, this understanding is
a vital prerequisite for developing better future therapies with potential
for wide-ranging implications. In this review, we discuss the current
views on the molecular basis of regulation of JAKs, as well as me-
chanisms of JAK deregulation in disease.
2. Jaks and the JAK–STAT pathway
JAKs are intracellular, non-receptor PTKs, but constitutively asso-
ciated with their cognate receptors [14–16]. There are four JAKs in
mammals, birds, and ﬁsh (JAK1–3, TYK2), with JAK1, JAK2 and TYK2
being ubiquitously expressed, while expression of JAK3 being mostly
restricted to cells of hematopoietic origin [17]. JAKs are multi-domain
proteins consisting of an N-terminal FERM-domain, a SH2-like domain,
a so-called pseudokinase domain (JAK homology 2, JH2) and the cat-
alytically active, signaling PTK domain (JH1). The FERM and SH2-like
domains mediate the interaction of JAKs with their receptors [18,19],
as well as regulating JAK kinase activity by as-of-yet unknown me-
chanisms [20,21]. Recent crystal structures have revealed that the
FERM and SH2 domains form a structurally tightly-linked continuous
unit with the receptor peptide running over, and intimately contacting
both domains [22–25].
The most deﬁning JAK domain is probably the pseudokinase do-
main, JH2, which constitutes the second kinase domain, and thus the
second face of its two-faced namesake ancient Roman god Janus. JH2
strongly resembles eukaryotic protein kinases, but shows a distinct
pattern of deviations from active kinases including lacking the catalytic
aspartate, which is replaced by an asparagine in all JAK JH2s, thus
gaining them the classiﬁcation of ‘pseudokinase’ [26–28]. JH2 has
critical regulatory functions, and is a veritable hotspot for clinically
relevant mutations, including driver mutations underlying hemato-
poietic malignancies (JAK2 mutations), leukemia and lymphomas (all
JAKs), and cancer (JAK1, JAK3), discussed in more detail below [5].
Lastly, JAKs consist of a C-terminal active PTK domain, JH1 , which is
closely related to the kinase domain of receptor tyrosine kinases (RTKs),
like epidermal growth factor receptor (EGFR), and seems to be evolu-
tionarily distinct from JH2 [29].
JAKs mediate signaling of around sixty diﬀerent cytokines, hor-
mones, and growth factors ranging from regulators of the immune
system and hematopoiesis, like interleukins (IL), interferons (IFN), er-
ythropoietin (EPO), and thrombopoietin (TPO), to regulators of devel-
opment and metabolism, like prolactin (PRL) and growth hormone
(GH) (see Table 1) [30]. Signaling through the JAK–STAT pathway
(Fig. 1A) is initiated by binding of a cytokine to the extracellular
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Fig. 1. The JAK–STAT signaling pathway and its regulation. A) Overview of the
JAK–STAT signaling pathway using erythropoietin (EPO) signaling as an ex-
ample. The most important intermolecular regulators are depicted along with
their point of action along the signaling pathway. B) Characterized phosphor-
ylation sites along JAK2. Activating phosphorylation sites are shown in green
and inhibiting in red. The eﬀect of Y206 phosphorylation on kinase activity is
uncertain. See also Table 3. C) The JH2–JH1 inhibitory interaction using JAK2
as an example [44]. Sites of known clinical activating JAK2 mutations are
shown with red spheres (α carbon), and most important mutations are high-
lighted. The two inhibitory phosphorylation sites, pS523 and pY570, are en-
circled. D) Close-up of the D873–R683 interaction, along with surrounding
residues, all of which are known sites of activating mutations (Table 2). E) The
phenylalanine stack around F617 in JAK2 V617F crucial for V617F-induced
JAK2 activation.
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portions of its cytokine receptor chain(s). This induces dimerization,
oligomerization, or a conformational change of the receptor complex
[31], which activates associated JAKs inducing trans-autopho-
sphorylation of the activation loop (AL) of JAK JH1s [32] and a sub-
sequent increase in catalytic activity [33]. The molecular details of this
activation mechanism are still unknown with multiple competing
models currently under investigation (see below) [34]. Activated JAKs
next phosphorylate speciﬁc tyrosines on the receptor chains, which
serve as docking sites for SH2 domain-containing signaling molecules
like STATs [35]. Receptor-bound STATs are next phosphorylated by
JAKs on a speciﬁc tyrosine in the C-terminal tail, enabling SH2-medi-
ated dimerization of STATs, and subsequent translocation into the nu-
cleus [35–37], where they act as transcription factors with far-reaching
eﬀects on regulation of transcription and epigenetics (reviewed in
[38]). This simple signal transduction pathway of cytokine receptors,
associated JAKs, downstream STATs, along with key protein regulators
is evolutionarily conserved throughout bilateria [39].
3. Regulation of JAK activity
Activity of the JAK–STAT pathway is tightly regulated on multiple
levels to ensure suppression of signaling in the absence of cytokine
stimulation, but also to allow rapid, transient activation upon stimu-
lation (Fig. 1). Regulation relies primarily on control of JH1 tyrosine
kinase activity by intra- and intermolecular mechanisms, as well as on
controlling the availability of parts of the signaling machinery. Many of
these levels of regulation are initiated or modulated by phosphorylation
of regulatory residues on JAKs, receptors, and STATs
3.1. Intramolecular regulation of JAK activity
The most basic level of regulation of JAK tyrosine kinase activity is
by the AL of JH1. Isolated JH1, when produced using recombinant
protein technology, is constitutively active and able to autopho-
sphorylate its AL in solution leading to full activation of the domain’s
enzymatic activity [33,40,41]. In PTKs, this phosphorylation is usually
necessary to relieve inhibition caused by the insertion of the unpho-
sphorylated AL into the active site of the domain [42]. However, no
crystal structures of JH1 currently exist of this presumed inactive form
[43], and recent molecular dynamics data have suggested, that acti-
vation of JH1 via phosphorylation of its AL is not (only) due to vacation
of the active site, but rather, due to destabilization of the autoinhibitory
JH2–JH1 interaction [44].
3.2. Inhibition and activation of JH1 by JH2
Early domain deletion experiments indicated that both JH2 and JH1
were needed for JAK-mediated signaling [45–48]. Subsequently, work
on JAK2 and JAK3 found that loss of JH2 was also associated with
increased basal JAK activity (i.e. in the absence of cytokine stimulation)
[47,48]. Furthermore, adding JH2 to isolated JH1 in cells or in re-
combinant constructs has been shown to signiﬁcantly decrease kinase
activity of JH1 [40,41,47,49]. Thus, JH2 is a regulatory domain with
two roles: ﬁrstly, inhibition of the kinase activity of JH1 in the absence
of stimulation and, secondly, mediation of the stimulatory signal from
the cytokine receptor to JH1 [48]. Both of these functions are strikingly
apparent in the eﬀects of various known clinical and experimental JAK
mutations, as JH2 harbors both gain-of-function and loss-of-function
mutations [46,50] (see Table 2).
Recently, virtually identical structures of a JH2–JH1 interaction
were proposed by long time scale molecular dynamics simulations for
JAK2 [44] and a crystal structure for TYK2 [41], which provide ex-
planation for JH2-mediated inhibition of JH1 (Fig. 1C). In the inter-
action, JH2 binds to the hinge-side of JH1 in a front-to-back orienta-
tion, loosely analogous to the interaction seen in the autoinhibited
structure of Src kinase, in which SH2-SH3 domains bind to the hinge-
side of the kinase domain [51]. In the JH2–JH1 interaction, JH1 ac-
tivity is probably inhibited by an opening of the catalytic site and
conformational restriction of the JH1 lobes preventing the conforma-
tional dynamics of JH1 needed for the kinase reaction.
The simulation-derived, autoinhibitory JAK2 JH2–JH1 interaction
includes two previously known, JAK2-speciﬁc inhibitory phosphoryla-
tion sites: JAK2 S523 and Y570 [52–55] (Fig. 1B, Table 3), phosphor-
ylation of both of which is expected to strengthen the interaction
(Fig. 1C) [44].
3.3. Activation of JAKs by mutation
The inhibitory JH2–JH1 interaction interface harbors the majority
of known clinical and experimental activating JAK mutations, and
disruption of the inhibitory interaction thus provides an explanation for
the hyperactive phenotype. Striking examples are mutations in JAK2
JH2 β7-β8 and αC-β4, and JH1 β2-β3 loops, which contain JAK2 R683
and D873 that form an ionic interaction over the JAK2 JH2–JH1 in-
terface (Fig. 1D). Mutations in these loops (including mutations of R683
and D873 themselves) are expected to weaken the JH2–JH1 interaction
by disrupting the R683–D873 link. Similarly, these residues are also
known mutation sites in other JAKs (Table 2), indicating that the
identiﬁed mode is likely to be conserved across all four JAKs. The
multitude of known JAK2 exon 12 mutations (Table 2), on the other
hand, fall into the SH2-JH2 linker region, which probably makes ex-
tensive contacts along the JH2–JH1 interface [44], and has previously
been shown to be important in suppression and regulation of basal
activity [19,56]. Similarly, mutations such as JAK2 V617 are expected
to disrupt the conformation of the SH2-JH2 linker, which is probably
(at least part of) the activation mechanism of, e.g., JAK2 V617F.
However, it is currently unclear, whether the high activating po-
tency of, e.g., JAK2 V617F is explained by SH2-JH2 linker-mediated
disruption of the JH2–JH1 interaction alone, or whether a distinct ac-
tivating intra- or intermolecular interaction is involved. Indeed, ana-
lysis of recombinant JAK2 fragments has shown that introduction of
V617F to JH2-JH1 constructs only increases catalytic activity by ∼3-
fold [40], suggesting that another mechanism beyond disruption of the
JH2–JH1 might be needed to explain the abnormally high activity of
JAK2 V617F in vivo. CoIP experiments with full-length JAK2 have
suggested that addition of the V617F mutation leads to a JAK2–JAK2
interaction in vitro, which cannot be detected with wild-type JAK2 [57].
The high density of activating mutations in the N lobe of JH2 as well as
the SH2-JH2 linker has also been suggested to be circumstantial evi-
dence for an activating interaction, probably involving these regions
[58]. Transformation by practically all activating JAK2 mutations (in-
cluding JAK2 V617F) requires the presence of cytokine receptors
[59–61], which could be due to requirements for an activating trans-
interaction. Alternatively, the receptor could function as a simple
scaﬀold allowing co-localization of activated JAKs with their substrate
(s). Data showing that correct orientation of the receptor chains are not
needed for activation by JAK2 V617F [62] support the latter model.
Analysis of experimental mutations capable of inhibiting activation
by clinical disease mutations (e.g., JAK2 V617F) has identiﬁed regions
in JH2 required for mutational activation. These regions include the
SH2-JH2 linker [63], a functional ATP-binding pocket in JH2 (at least
in JAK1, JAK2 [64], and JAK3 (Raivola, Hammarén, Silvennoinen et al,
manuscript in preparation)), as well as JH2 αC [62,65,66]. Indeed,
molecular dynamics simulations of JAK2 JH2 suggest that V617F in-
duces stabilization of JH2 αC, which can be reversed by addition of the
inhibiting αC mutation JAK2 F595A thus breaking the phenylalanine
stack around F617 (Fig. 1E) [67]. Similarly, loss of JH2 ATP-binding is
likely to suppress mutational activation by destabilizing αC [64]. In-
terestingly, these mutations have been reported to not strongly inhibit
cytokine-dependent JAK activation, suggesting that activation by cy-
tokine could be mechanistically distinct from activation by mutations
like JAK2 V617F [57,62,64–66]. Whether this is due to a distinct
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Table 2
Clinical mutations in JAKs. Data in the table were expanded from similar compilations in [41,165–167]. Kinase activity – measured as basal JAK activation loop
phosphorylation (e.g., JAK2 Y1007/1008), STAT phosphorylation, or transcriptional activity in reporter assay: +/− increase/decrease in activity, respectively. An
increase in activity (+) refers to basal (unstimulated) activity (e.g., ligand-independent activation by JAK2 V617F); for decreased activity (−) signaling upon
stimulation is included (e.g., cytokine-irresponsive JAK3 SCID mutations); NE – no appreciable eﬀect. fs – frame-shift. Due to the increased pace of genetic analysis of
patient samples, experimentally uncharacterized mutations are only shown, if of special interest.
Exon # JAK domain Mutation Kinase
activity
Eﬀect Associated disease Reference
JAK1
3 FERM I62V B-ALL and T-ALL [168]
3 FERM S71C ETP-ALL [169]
4 FERM D82A Might lower receptor association (shown together with
JAK1 Y81A)
Gynecologic tumors [167,170]
5 FERM K142fs LOF by frame-shift Gynecologic tumors [167]
6 FERM K204M B-ALL [167]
8 FERM N339fs LOF by frame-shift Gynecologic tumors [167]
8 FERM R360W T-ALL [168]
8 FERM I377K ETP-ALL [169]
9 Linker V427M Pediatric T-ALL [171]
9 Linker N451S + Increased pSTAT3/5 Hepatocellular carcinoma (xenograft) [172]
9 Linker P430fs LOF by frame-shift Gynecologic tumors [167]
10 SH2 W467* Breast Cancer (Triple Neg) [173]
10 SH2 T478S + Increased pSTAT1/3/5 AML [41]
10 SH2 E483D + Increased pSTAT3/5 Hepatocellular carcinoma (xenograft) [172]
11 SH2 G511D Gynecologic tumors [167]
11 SH2 S512L Overexpression of ALL (and JAK)-related genes T-ALL [168]
12 Linker R577Q Gynecologic tumors [167]
13 JH2 T593M Gynecologic tumors [167]
13 JH2 D604Y T-ALL [174]
13 JH2 V623A + Increased pSTAT1/3/5 AML [41]
13 JH2 L624-629W ALL [175]
13 JH2 I631R/G/I ALL [176]
14 JH2 A634D + B-ALL and T-ALL [168]
14 JH2 E637K Breast Cancer (HER2+) [173]
14 JH2 Q644H Hepatocellular carcinoma [123]
14 JH2 V645F + Constitutive pJAK1/STAT5 Hepatocellular carcinoma [123]
14 JH2 S646F/P + Increased pJAK1/STAT5 ALL [175,177]
14 JH2 H647Y Invasive ductal carcinoma [178]
14 JH2 K648N T-ALL [179]
14 JH2 V651M T-ALL [41]
14 JH2 Y652H + Constitutive STAT5 activity T-ALL [41,177]
14 JH2 L653F + Childhood ALL [168]
14 JH2 C657R Gynecologic tumors [167]
14 JH2 V658F/L + Constitutive STAT5 activity ALL [175,177,178,180]
15 JH2 E668Q + Pediatric T-ALL [171]
15 JH2 S703I + High basal pSTAT3/5 ALL & hepatocellular carcinoma [172,176,177]
16 JH2 R724H/Q/S + Increased STAT1 activity B-ALL and T-ALL [168]
16 JH2 S729C + Increased pSTAT3/5 Hepatocellular carcinoma (xenograft) [172]
16 JH2 P733L − Immunosuppression [181]
16 JH2 F734L T-ALL [177]
17 JH2 T782M Adenocarcinoma [178]
17 JH2 L783F + Increased STAT5 activity T-ALL [177,178]
17 JH2 L799P Gynecologic tumors [167]
18 Linker P832S − Immunosuppression [181]
19 Linker K860fs − LOF by frame-shift Gynecologic tumors [167]
19 Linker G871E SKN tumour cell line [182]
19 JH1 R879S/C/H + Increased STAT1 activity T-ALL [168]
19 JH1 G882E Loss of JH1 ATP-binding SKN tumour cell line [182]
20 JH1 T901G + T-ALL [171]
20 JH1 K908T Pediatric T-ALL [171]
20 JH1 K924fs LOF by frame-shift Gynecologic tumors [167]
22 JH1 G990_splice Gynecologic tumors [167]
23 JH1 E1051Q/P Gynecologic tumors [167]
24 JH1 A1086S + Increased pSTAT3/5 Hepatocellular carcinoma (xenograft) [172]
24 JH1 R1113H Gynecologic tumors [167]
JAK2
3 FERM E61K Putative primary erythrocytosis [183]
4 FERM T108A NE Slightly EPO hypersensitive Found as germline mutation in V617F-
positive PV patient
[184]
6 FERM E177V Putative primary erythrocytosis [183]
7 FERM G276A Putative primary erythrocytosis [183]
8 FERM R340Q PV [185]
9 Linker L393V NE Might be weakly EPO hypersensitive Found as germline mutation in V617F-
positive PV patient
[184]
SH2
12 Linker T514M MPNs [186]
(continued on next page)
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Table 2 (continued)
Exon # JAK domain Mutation Kinase
activity
Eﬀect Associated disease Reference
12 Linker N533I/Y PV (together with K539L) [166]
12 Linker M353I + AMKL [19]
12 JH2 K539L + MPNs [187]
12 JH2 I540T PV [41]
12 JH2 538–547 (Various deletions and insertions) MPNs [41,188]
12 JH2 D544G PV [41]
12 JH2 L545S PV [41]
12 JH2 F547L PV [41]
13 JH2 F556L MPNs [166]
13 JH2 R564Q + Hereditary ET [189]
13 JH2 V567A MPNs [166]
13 JH2 G571S Unknown (non-aﬀected parent of MPN
patient has this variant)
[183]
13 JH2 H587N MPNs [166]
13 JH2 S591L MPNs [166]
14 JH2 H606Q MPNs [166]
14 JH2 K607N + AML [166]
14 JH2 H608Y MPNs [166]
14 JH2 L611S + ALL [166]
14 JH2 V617F + MPNs [116–119]
14 JH2 V617I (+) Cytokine hyperresponsiveness Hereditary thrombocythemia [190,191]
14 JH2 C618R + MPNs [192]
14 JH2 D620E MPS [193]
15 JH2 L624P MPNs [166]
15 JH2 I645V MPNs [166]
16 JH2 I682F + ALL [194]
16 JH2 R683S/G + MPNs [194,195]
17 JH2 S755R Hereditary thrombocythemia (together
with R938Q in cis)
[196]
19 Linker Y813D IMF [41]
19 Linker E846D (+) Increases JH1 activity, when EPOR is present, EPO
hypersensitivity
Germ-line mutation found in erythrocytosis
and megakaryocytic atypia
[197]
20 JH1 R867Q + ALL, hereditary thrombocythemia [175,196]
20 JH1 D873N + ALL [194]
20 JH1 T875N + AMKL [41]
21 JH1 P933R + ALL [194]
21 JH1 R938Q + Hereditary thrombocythemia (together
with S755R in cis)
[196]
24 JH1 R1063H (+) Increases JH1 activity, when EPOR is present, EPO
hypersensitivity
Germ-line mutation found in erythrocytosis
and megakaryocytic atypia
[197]
25 JH1 N1108S PV [41]
JAK3
2 FERM M1V SCID [165]
2 FERM G36fs − LOF by frame-shift SCID [198]
2 FERM A58P/del − Lack of JAK3 mRNA/protein SCID [165,198]
3 FERM G62S + Does not transform BaF3, kinase activity higher than
WT
AML [199]
3 FERM I87T + Increased basal pJAK3/pSTAT5 DS-TMD [198,200]
3 FERM L98/99A Weakens receptor binding SCID [201]
3 FERM Y100C − Weakens receptor binding SCID [201,202]
4 FERM P132T/A + P132A oncogenic in mouse xenotransplants AMKL [203,204]
5 FERM P151R SCID, DS-TMD, AMLK [165,205]
5 FERM L156P + No signiﬁcant increase in pSTAT5 in 293T cells, but
does transform BaF3 cells
ATLL [206]
5 FERM D169E − No IL-2 responsive pSTAT5 SCID [24]
5 FERM R172Q + No signiﬁcant increase in pSTAT5 in 293T cells, but
does transform BaF3 cells
ATLL [206]
5 FERM E183G + ATLL [206]
6 FERM R223H Small cell carcinoma/neuroendocrine
prostate cancer (NePC)
[207]
6 FERM R272H Nontransforming passenger T-ALL [208]
6 FERM Q283H Nontransforming passenger T-ALL [209]
8 FERM T391fs LOF by frame-shift SCID [198]
9 SH2 R403H Nontransforming passenger T-ALL [208,210]
10 SH2 R445X − SCID [211]
11 SH2 E481G − SCID [212]
11 Linker K482S SCID [165]
Linker fsX483 LOF by frame-shift SCID [165]
11 Linker del482-596 − SCID [212]
11 Linker Q501H + AMKL [41,200]
11 Linker Q507P T-PLL [213]
11 Linker M511I + Slight kinase activity increase, transforms Ba/F3 T-PLL, AML, JMML, NKTCL [208,213]
12 JH2 C565X − SCID [108,198]
(continued on next page)
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Table 2 (continued)
Exon # JAK domain Mutation Kinase
activity
Eﬀect Associated disease Reference
13 JH2 A572V/T + Increased pSTAT3/5; features of megakaryoblastic
leukemia and transforms murine lymphoid cells in vivo
AMKL [41,208]
13 JH2 A573V + T-ALL-like disease in mice DS-ALL,DS AMKL, NTCL [41,208,214–216]
13 JH2 M576L Adult non-DS AMKL [217]
13 JH2 del586-592 − No pSTAT5, but constitutive pJAK3 SCID [49]
13 JH2 R582W − Leads to two products, insuﬃcient for signal
transduction
SCID [165]
13 JH2 H583Y + NTCL [198,216]
13 JH2 G589S − SCID [198]
13 JH2 G589D + NTCL [216]
13 JH2 delV590-S596 SCID [165]
13 JH2 del592 AMKL/TMD [205]
13 JH2 A593R/T + DS-AMKL [41,215]
15 JH2 R657Q(/H/W) + High basal pSTAT5, causes B-cell leukemia in mice T-PLL, AML, JMML, NKTCL [41,213]
15 JH2 R651W SCID [218]
15 JH2 V674A/F + Increased STAT5 activation, T-ALL-like disease in mice T-ALL [213,219,220]
15 JH2 V678L/M T-ALL [208,213]
16 JH2 P689S SCID [218]
16 JH2 R694K SCID [218]
16 JH2 E698X SCID [165]
16 JH2 V715I Breast cancer [178]
16 JH2 V722I + AMKL, SCID,NKTCL [203,211]
16 JH2 K733fs LOF by frame-shift SCID [221]
17 JH2 Del734-784 SCID [165]
17 JH2 C759R − No pSTAT5, but constitutive pJAK3 SCID [49]
17 JH2 V765D JMML [222]
17 JH2 Q766X SCID [165]
17 Linker R771X SCID [165]
18 Linker S789P + Increased kinase activity, but only weakly transforms
BaF3
Childhood ALL [194,215]
18 JH1 Y824D T-PLL [223]
19 JH1 L857Q/P + Receptor independent, L857Q causes severe thymus
hyperplasia in mice
T-ALL/T-PLL/JMML [208,220]
19 JH1 Q865E Nontransforming passenger T-ALL [209]
19 JH1 fsX844 LOF by frame-shift SCID [165]
20 JH1 Y904X SCID [224]
20 JH1 P906S + ALL [220]
20 JH1 L910S − SCID [218]
20 JH1 R918C + Increased kinase activity, but only weakly transforms
BaF3
AML [199,215]
20 JH1 R925S Nontransforming passenger T-ALL [208]
20 JH1 Y929X SCID [198]
21 JH1 E958K + T-ALL, JMML [209,220,222,225]
21 JH1 G987fs − LOF by frame-shift SCID [198]
21 JH1 Q988P T-ALL [226]
22 JH1 L1017M + Increased kinase activity, but only weakly transforms
BaF3
CML [199]
22 JH1 Y1023X − SCID [218]
23 JH1 1024fs − LOF by frame-shift SCID [165]
24 JH1 E1106G Nontransforming passenger T-ALL [208]
TYK2
3 FERM G36D T-ALL (MOLT-16 cell line) [134]
3 FERM S47N T-ALL (MOLT-16 cell line) [134]
3 FERM A53T NE PBMCs show decreased CXCL10 response Increased MS risk, found in herpes simplex
encephalitis (HSE) patient
[227–229]
8 FERM V362F NE Increased SLE and SSc risk [230]
8 FERM G363S NE AML [228]
9 FERM R425H T-ALL (MOLT-16 cell line) [134]
Linker
SH2
Linker
15 JH2 I684S − Impairs TYK2 kinase activity, but still enables signaling
through JAK1/TYK2 or JAK2/TYK2
Protect against RA and Autoimmunity. Also
found in T-ALL.
[134,231,232]
15 JH2 R703W NE AML [228]
16 JH2 V731I + ALL (RPMI-8402 cell line) [134]
16 JH2 P760L + ALL (germline) [135]
16 JH2 G761V + ALL (germline) [135]
Linker
20 JH1 M926V NE Germline mutation in ALL, but probably
not deleterious
[135]
20 JH1 A928V NE Protect against RA and Autoimmunity [228,231]
20 JH1 E957D + ALL (MOLT-4 cell line) [134,135]
22 JH1 A1016S NE AML [228]
(continued on next page)
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activating interaction employed by, e.g., JAK2 V617F, is still unknown.
3.4. Phosphorylation as mediator of regulation
Much of the regulation of JAK–STAT signaling is controlled by
phosphorylation (Fig. 1B). In the basal state, JAK2 (for which there is
the most data available) is phosphorylated only on S523 (potentially by
JH2 itself [54,68]), which strengthens the JH2–JH1 interaction de-
scribed above [44]. Upon activation of receptor by cytokine, JAK2 is
activated by (trans-)autophosphorylation not only on the JH1 AL
(Y1007/Y1008), but also on multiple other residues (Y637, Y868,
Y966, Y972), which are needed for full activation of kinase activity by
as-of-yet unknown mechanisms (Table 3) [69]. Termination of sig-
naling is subsequently initiated by phosphorylation of numerous in-
hibitory residues along JAK2 (Fig. 1B, Table 3), which may cause dis-
sociation of JAK2 from its receptors (Y119 [70]), strengthen the
JH2–JH1 inhibitory interaction (Y570, Fig. 2C [44,68,69]), or act as
binding sites for regulatory proteins.
Likewise, dephosphorylation of both JAK and receptor activating
tyrosines is an important part of regulation of signaling, and is induced
by multiple protein tyrosine phosphatases (PTP), including SH2
domain-containing phosphatases 1 and 2 (SHP1, SHP2), PTP1B, T-cell-
PTP (TCPTP), Receptor-type PTPs C (PTPRC/CD45) and T (PTPRT), as
well as basophil-like PTP (PTPBL) (reviewed in [71]). Notably, SHP2,
which is a known oncoprotein and increasingly interesting drug target
itself [72], has been reported to be both an activator and suppressor of
JAK–STAT signaling depending on the context [71]. Other phospha-
tases associated with regulation of JAK–STAT signaling function as
classical negative regulators of signaling in termination or basal sup-
pression of signaling (reviewed in [34,71]). Most recorded phosphor-
ylation events on JAK2 have been shown to be dependent on JAK2 JH1
kinase activity (or AL phosphorylation), but the exact sequence of
phosphorylation events or their mechanism of action during receptor-
mediated activation is yet to be fully elucidated. Potential diﬀerences in
phosphorylation-mediated regulation in diﬀerent cytokine re-
ceptor–JAK contexts also remain mostly unknown.
3.5. Intermolecular regulation of JAK activity
Most known intermolecular modes of JAK–STAT signaling regula-
tion are involved in termination of signaling after cytokine stimulation,
and are thus initiated by phosphorylation during cytokine-mediated
Table 2 (continued)
Exon # JAK domain Mutation Kinase
activity
Eﬀect Associated disease Reference
22 JH1 R1027H + ALL (MOLT-16 and CCRF-CEM cell lines) [134]
23 JH1 P1104A − Impairs TYK2 kinase activity, but still enables signaling
through JAK1/TYK2 or JAK2/TYK2
Decreased susceptibility to RA and
Autoimmunity; Found in NF1-MPNSTs
[228,231–233]
Table 3
Regulatory phosphorylation sites, their eﬀect on basal JAK2 activity (measured as pJAK2 (pY1007/Y1008) or a downstream measure like STAT phosphorylation
(pSTAT) or transcriptional reporter activity), the probable phosphorylating kinase, and assumed eﬀects of phosphorylation (mostly based on mutagenesis experi-
ments) are shown. Cytokines, which have been experimentally tested for inducing speciﬁc phosphorylation, are shown in parenthesis. Sites for which no functional
follow-up data has been published, have been omitted for clarity (see, e.g. [234,235]). NE – no eﬀect. Autophos. – autophosphorylation by full-length JAK2. ? – no
data available.
Domain JAK2
Residue
Kinase
activity
Phosphorylated upon Phosphorylated by Eﬀect of phosphorylation/mutation of site References
FERM Y119 − Stimulation (EPO) Probably JH1* Phosphorylation likely to mimic Y119E, which induces
dissociation from EPOR, GHR, PRLR, but not IFNGR2
[70]
FERM Y201 +§ ? Autophos. (in vitro) Y201F inhibits Ang II-mediated JAK2-signalling§ [69,237]
FERM Y206 NE ? ? Y206F has no appreciable eﬀect on EPO signaling [69,237]
FERM Y221 + Stimulation (GH, IL-3) Autophos. (in vitro and in
cells)
Y221F decreases basal pJAK2 [52,53]
FERM Y317 − Stimulation (EPO) Probably mostly JH1* Y317F causes ligand-independent pJAK2 [69]
FERM Y372 + ? ? Y372F decreases basal and stimulated (IFN-γ, EGF) pJAK2,
pSTAT1 and JAK2-STAT1 interaction
[69,238]
FERM Y373 + ? ? Y373F decreases basal pJAK2 [238]
SH2
Linker S523 − Constitutive JH2 (in vitro) S523A slightly increases basal pJAK2 [54,55,68]
JH2 Y570 − Stimulation (GH, EPO, IL-
3)
Autophos. (in vitro), JH2
(in vitro)
Y570F increases basal pJAK2, pSTAT3 and prolongs EPO-
induced activity. pY570 likely to strengthen autoinhibitory
JH2–JH1 interaction
[41,44,52,53]
JH2 Y637 + Stimulation (EPO) Probably mostly JH1* Y637F lessens and shortens JAK2 activation upon EPO
stimulation and partially inhibits V617F
[69]
Linker Y813 + Stimulation (GH) Autophos. (in vitro) Y813F reduces SH2-Bβ induced pJAK2 and pSTAT5. pY813
putative binding site for activator protein SH2-Bβ
[239]
JH1 Y868 + Stimulation (GH) JH1 (in vitro) Y868F decreases basal and GH-induced pJAK2, pSTAT3/5 [240]
JH1 Y913 − Upon and after stimulation
(EPO)
Probably JH1* Y913F increases EPO-induced pJAK2/pSTAT5. Y913E removes
EPO-induced JAK2 activation
[241]
JH1 Y966 + Stimulation (GH) JH1 (in vitro) Y966F decreases basal and GH-induced pJAK2, pSTAT3/5 [240]
JH1 Y972 + Stimulation (GH) JH1 (in vitro) Y972F decreases basal and GH-induced pJAK2, pSTAT3/5 [240]
JH1 Y1007 + Stimulation JH1 Y1007F removes basal and cytokine-induced JAK2 activation
and downstream signaling. pY1007 likely to weaken JH2–JH1
interaction
[32,33,44]
JH1 Y1008 NE Stimulation JH1 Y1008F has little eﬀect on JAK2 activation [32]
* Dependent on JAK2 Y1007/Y1008 phosphorylation and/or JH1 kinase activity.
§ Y201F has no eﬀect on EPO-induced pJAK2, but inhibits Ang II-mediated pJAK2, pSTAT1/3. Phosphorylation probably enables binding of SHP2 and subsequent
binding to AT1 receptor. Y201F has also been shown to inhibit activation by JAK2 V617F [236].
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activation. Mechanisms of termination involve (de)phosphorylation,
production of inhibitory proteins, and removal of signaling complexes
through internalization and lysosomal or ubiquitination-mediated
proteasomal degradation of receptors [5,34].
One family of direct inhibitory proteins are suppressors of cytokine
signaling (SOCS1–7 and CIS), transcription of which is upregulated by
activated STATs, thus forming a negative feedback loop [73]. The
mechanism for SOCS-mediated inhibition has been revealed for SOCS3,
which binds to both JH1 and the associated cytokine receptor, leading
to inhibition of JH1 activity by direct interaction with the JH1 AL, in
addition to initiation of ubiquitination of JAKs [74,75].
Active JAK–STAT signaling also induces transcription of SH2B fa-
mily proteins (consisting of SH2B1/SH2-B, SH2B2/APS, and SH2B3/
LNK), which each consist of a dimerization domain (DD), Pleckstrin
homology (PH) domain and a C-terminal SH2 domain. SH2-B and APS
bind to phosphorylated receptor or JAK tyrosines (e.g. JAK2 pY613 and
pY813) via their SH2 domain [76–79], and are able to either activate or
inhibit JAK activation, potentially by acting as dimerization scaﬀolds
for JAKs [80]. The activating role of SH2-B has been most compre-
hensively demonstrated in leptin–JAK2 signaling [78,81], and muta-
tions or deletions in SH2B1 have been linked to severe obesity (see
Table 4). Interestingly, SH2-B has also been reported to bind to EPOR
and putatively act as a negative regulator of EPOR signaling [82]. The
third SH2B family member, LNK is a well-deﬁned inhibitor of JAK2, as
well as potentially JAK3 (reviewed in [79]). How LNK negatively reg-
ulates JAK activity is not clear, but it is likely to involve a direct in-
teraction with the LNK N-terminal domains and JAK kinase domains,
and/or ubiquitination via recruitment of E3 ligases [79].
JAK–STAT signaling is also regulated at the level of STATs by pro-
tein inhibitor of activated STATs (PIAS) proteins, which are one of only
few known small ubiquitin-like modiﬁer (SUMO) E3 ligases (see [83]
for a review). As their name suggests, PIAS proteins (consisting of
PIAS1, PIAS3, PIASx, and PIASy) were ﬁrst identiﬁed as negative reg-
ulators of STATs [84,85], but they have since been shown to also be
involved in regulation of multiple other cellular processes [86]. Fol-
lowing cytokine stimulation, PIAS proteins have been shown to inhibit
STAT signaling activity through inhibition of their DNA-binding ac-
tivity by directly interacting with STATs and and/or by inducing STAT
SUMOylation (reviewed in [87]).
3.6. Activation of JAKs by cytokines – The role of the cytokine receptor
Despite long-continuing research into the mechanisms of JAK acti-
vation by mutation and intermolecular regulation by various negative
regulator proteins, the molecular mechanisms of JAK activation on
cytokine receptors following cytokine stimulation have mostly re-
mained elusive. One complicating factor is the sheer number of dif-
ferent JAK-associated receptors (Table 1) and their variable archi-
tectures. These range from ‘short receptors’ (e.g., GHR, EPOR, γc family,
IFNGR) where ligand-binding domains are proximal to the membrane,
and ‘tall receptors’ (e.g., gp130, TCCR, LIFRβ) with ligand-binding
domains up to 10 nm removed from the membrane [88–91]. Numerous
crystal structures of receptor extracellular domains have been gener-
ated showing cytokine-bound and unbound states [90], but how these
changes are translated into intracellular activation of JAKs is not
known.
The simplest mode of cytokine receptor activation is an induced
dimer/oligomer model, where ligand binding induces dimerization/
oligomerization of receptor chains and associated kinases, which are
subsequently activated by transphosphorylation due to proximity. This
mode is widely seen in RTKs [92,93], with exceptions like insulin re-
ceptor kinase (IRK), which seems to exist as preformed dimers rear-
ranged by ligand binding [94]. Studies with engineered artiﬁcial chi-
meric receptors have shown that simple dimerization is suﬃcient to
activate JAKs [95] suggesting an induced-dimer activation model.
Nevertheless, preformed dimers have been reported for many JAK-
associated receptors, including EPOR [96], GHR [97], gp130 [98],
LEPR [99], as well as IL-2Rβ/IL-9Rα and γc [100]. However, some of
these data may be confounded by the use of artiﬁcial overexpression
systems and/or dimerization-prone fusion proteins. A current lack of
methods to simultaneously measure receptor oligomerization and ac-
tivation states also leaves it unclear, how many of the observed pre-
formed dimers are actually actively signaling and thus contributing to
basal signaling activity. Still, studies with forced EPOR or TPOR dimers
have indicated that correct orientation of receptor chains is needed for
activation of wild-type JAK2, thus potentially enabling non-signaling
preformed dimers in vivo [101–103]. Additionally, FRET-studies with
forced preformed GHR dimers suggested that the intracellular portions
of GHR would move apart during stimulation, leading the study authors
to hypothesize that JH2-mediated inhibition of JH1 could occur in trans
at least for JAK2 [104]. How, or whether this architecture would apply
to heteromeric JAK conﬁgurations, is unclear.
Despite these earlier ﬁndings, recent single-molecule imaging stu-
dies have shown a distinct lack of preformed dimers for EPOR at least,
and approaches using engineered protein ligands have suggested that
activation of EPOR–JAK2 is mainly determined by the distance between
receptor chains [105], thus again arguing for a ligand-induced dimer
model [91]. Further research using less invasive methodology with (at
least close to) native expression levels of receptors is thus sorely needed
to settle the question of receptor-mediated activation of JAKs.
4. Failure of JAK regulation leads to disease
Failure of JAK–STAT pathway regulation is a common cause of
myeloid and lymphoid disorders but also plays a role in multiple can-
cers (Table 4) [6,7,106]. The ﬁrst JAK disease-link was discovered in
1995 when JAK3 loss-of-function mutations were reported causative of
severe combined immune deﬁciency (SCID) [107,108]. Shortly later,
inhibition of acute lymphoblastic leukemia (ALL) with JAK-inhibitor
AG-490 lead to the discovery of constitutive JAK2 activity in patient-
derived ALL cells [109]. Subsequently constitutively active JAK2 fusion
protein TEL/ETV6-JAK2 was identiﬁed in early pre-B cell ALL and T-
cell childhood ALL [1,110].
Oncogenic JAK2 rearrangements to multiple fusion gene partners
(TEL, PCM1, BCR, SSPB2, STRN3, RPN1, NF-E2, RUNX1, SEC31A,
SPAG9) have since been identiﬁed in ALL, acute myeloid leukemia
(AML), atypical chronic myeloid leukemia (CML), MPN and/or
Hodgkin lymphoma [2,110–114], and similar oncogenic fusions have
also been reported for TYK2 [106]. The chimeras comprise of JH1, with
or without (pieces of) JH2, fused to dimerization domain(s) of the fu-
sion partner, leading to constitutive tyrosine kinase activity presumably
via dimerization/oligomerization [1,112,115]. These translocations are
rare, however: a cytogenetic study of 24 262 unique patients, for ex-
ample, revealed these kinds of JAK2 abnormalities in only 0.06% of
hematopoietic neoplasms [113].
In contrast, somatic JAK2 V617F is highly prevalent in MPN and
causes approximately 95% of polycythemia vera (PV) and 50–60% es-
sential thrombocythemia (ET) and primary myeloﬁbrosis (PMF) cases
[116–119]. Allelic burden probably plays a role in deﬁning the clinical
phenotype of JAK2 V617F as the burden increases from ET over PV to
PMF [120]. Furthermore, the pSTAT proﬁles discriminate among the
MPN diseases and are independent of JAK2 V617F: high pSTAT3 and
pSTAT5 are typical in PV, high pSTAT3 and low pSTAT5 in ET, and low
pSTAT3 and pSTAT5 in PMF [121], but the mechanism behind these
diﬀerences have remained largely unknown. PV, ET and PMF can
evolve into AML and therefore it is not surprising that approximately
5% of AML patients are also V617F-positive [122]. Numerous gain-of-
function mutations identiﬁed in JAK1, JAK2 and JAK3 (Table 2) are
drivers in∼20% of T-ALL cases (mainly JAK1, also JAK2, JAK3) and to
lesser extent in B-ALL (JAK1, JAK2) or hepatocellular adenoma (JAK1)
[5,123].
V617F-negative MPN often show mutations in other components or
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regulatory elements of the JAK–STAT pathway. For example, 1–5%
PMF and ET patients carry point mutations (e.g., S505N, W515L/K/R)
in the thrombopoietin receptor (TPOR) gene MPL [124], which enable
ligand-independent activation of TPOR–JAK2 signaling [125,126].
Relatively common are also calreticulin (CALR) frameshift mutations
causing TPO-independent TPOR–JAK2 signaling in up to ∼13% of
MPNs. CALR is a multifunctional endoplasmic reticulum protein, and its
common frameshifts result in the formation of a highly-charged protein
structure at the C-terminus of mutated CALR, which has been shown to
be able to directly bind to the ligand-binding domain of TPOR, thus
activating the receptor [127,128]. Another MPN-linked activation me-
chanism through TPOR is caused by mutations in the inhibitory adaptor
protein LNK, which lead to mislocalization of LNK from the plasma
membrane into the cytoplasm and result in TPO hyper-responsiveness
[129]. LNK mutations are found in 5–7% of MPNs [130].
Besides disease-causing mutations hyperactivating JAK–STAT sig-
naling, also deleterious loss-of-function mutations in the JAK–STAT
regulatory apparatus have been described. Probably most famously,
loss-of-function (LOF) germline mutations in JAK3 or JAK3-associated
receptors IL-7R and common gamma chain (γc; also known as CD320 or
IL-2RG) cause autosomal recessive SCID [131]. In fact, JAK3/IL-7R/γc
mutations cover the majority of all SCID cases: JAK3 mutations account
for approximately 10–18% of heritable SCID, IL-7R < 10%, and γc
25–46% [131]. Although JAK3 SCID-associated mutations are found in
all JAK domains, the majority is located either in JH2 or the FERM
domain (Table 2). Known JAK3 mutations include frameshifts and
nonsense mutations (readily explaining LOF), but interestingly also
point mutations, for all of which the mechanism action has not been
conclusively determined (Table 2). Some JAK3 mutations are, however,
known to aﬀect protein expression and structural stability, or less
commonly hinder receptor binding (e.g. JAK3 Y100C) [131].
Knowledge about diseases caused by TYK2 mutations has only lately
started to emerge. TYK2 deﬁciency caused by frameshift mutations has
been reported in two primary immunodeﬁciency (PID) patients, one
with and one without hyper-IgE syndrome [132,133]. Activating driver
TYK2 mutations have recently been found in multiple ALL cell lines
[134] and patient samples, including two gain-of-function germline
TYK2 mutations [135]. Additionally, multiple TYK2 polymorphisms
have been described, some of which alter the activity of the protein and
are associated with increased or decreased risks for autoimmune or
inﬂammatory diseases (Table 2).
SOCS as regulators of JAK-STAT pathways have critical functions in
pathogenesis of inﬂammatory and other immune disorders, suscept-
ibility to infectious diseases and development and progression of cancer
[136,137]. SOCS are suggested to have tumor suppressive role and
decreased SOCS levels due to DNA hypermethylation of one or more
SOCS genes have been observed in multiple cancers, such as hepato-
cellular carcinoma, cholangiocarcinoma, Hodgkin lymphoma, and pri-
mary mediastinal B-cell lymphoma. Furthermore, reduced expression of
SOCS3 was shown to associate closely with lymph node metastasis in
breast cancer [138]. Elevated SOCS levels possibly caused by certain
SOCS promoter variants have been found in asthma (SOCS1, 3), RA
(SOCS1, SOCS3), and atopic dermatitis (SOCS3) [136,139–141].
Although outside of the scope of this review, the role of various
STAT mutations in development of immunological diseases cannot be
underestimated as they lead to similar clinical phenotypes as dereg-
ulation of the upstream components. For recent reviews see [142,143].
5. Future outlook and perspectives
Current clinical and pharmacological interest in JAKs is at an all-
time high. JAK inhibition has proven to be eﬀective not only in diseases
directly caused by activating deregulation of the JAK–STAT pathway
(e.g., JAK2 mutation-driven MPNs), but also in diseases, in which JAKs
act as mediators and ampliﬁers of proinﬂammatory signals, even
though the disease might not be caused by deleterious changes in the
JAK–STAT pathway itself. This is the case for RA for which two JAK
inhibitors are already FDA and EMA-approved (tofacitinib, baricitinib),
and potentially many other inﬂammatory diseases currently under in-
vestigation.
Similarly, understanding of the regulatory mechanisms governing
the JAK–STAT pathway has grown steadily. Nevertheless, molecular
understanding of JAK activation and inhibition is still far from com-
plete. Detailed elucidation of the mechanisms of JAK inhibition and
activation on receptors especially will be key for the development of
modulators of JAK activity with novel modes of actions. The need for
these kinds of novel inhibitors is great, and the ﬁelds of application
wide. All current JAK inhibitors (‘Jakinibs’) target the catalytic ATP-
binding site of JH1, which are highly similar between JAKs, making
speciﬁcity within the JAK family problematic for most inhibitors.
Furthermore, current inhibitors cannot distinguish between mutated
JAKs (e.g. JAK2 V617F in MPNs) and wild-type JAKs leading to po-
tential side-eﬀects and an inability to eradicate diseases caused by so-
matic JAK mutations.
Encouragingly development of multiple novel JAK activity-mod-
ulator types is already underway. These include covalent inhibitors
against JAK3 JH1 [144], compounds targeting the ATP-binding site of
JH2 [145–148], protein-protein interaction interfaces within JAK
[149], and the extracellular parts of JAK-associated receptors [91].
These targets have the potential to deliver more speciﬁcity (including
mutant-speciﬁcity over wild-type JAK), as well as safety.
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